Skip to Content
Merck

Hologram QSAR model for the prediction of human oral bioavailability.

Bioorganic & medicinal chemistry (2007-09-18)
Tiago L Moda, Carlos A Montanari, Adriano D Andricopulo
ABSTRACT

A drug intended for use in humans should have an ideal balance of pharmacokinetics and safety, as well as potency and selectivity. Unfavorable pharmacokinetics can negatively affect the clinical development of many otherwise promising drug candidates. A variety of in silico ADME (absorption, distribution, metabolism, and excretion) models are receiving increased attention due to a better appreciation that pharmacokinetic properties should be considered in early phases of the drug discovery process. Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects. In the present work, hologram quantitative structure-activity relationships (HQSAR) were performed on a training set of 250 structurally diverse molecules with known human oral bioavailability. The most significant HQSAR model (q(2)=0.70, r(2)=0.93) was obtained using atoms, bond, connection, and chirality as fragment distinction. The predictive ability of the model was evaluated by an external test set containing 52 molecules not included in the training set, and the predicted values were in good agreement with the experimental values. The HQSAR model should be useful for the design of new drug candidates having increased bioavailability as well as in the process of chemical library design, virtual screening, and high-throughput screening.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Levofloxacin, 98.0-102.0% anhydrous basis (HPLC)
Supelco
Mettler-Toledo Calibration substance ME 18872, Caffeine, traceable to primary standards (LGC)
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Supelco
Dapsone, VETRANAL®, analytical standard
Sigma-Aldrich
Caffeine, anhydrous, 99%, FCC, FG
Sigma-Aldrich
(S)-(+)-Ibuprofen, ReagentPlus®, 99%
Sigma-Aldrich
1α,25-Dihydroxyvitamin D3, ≥97.0% (HPLC)
Sigma-Aldrich
Caffeine, anhydrous, tested according to Ph. Eur.
Sigma-Aldrich
Melphalan, powder
Sigma-Aldrich
6α-Methylprednisolone, ≥98%
Sigma-Aldrich
5-Fluorocytosine, nucleoside analog
Supelco
Δ9-Tetrahydrocannabinol solution, 1.0 mg/mL in methanol, analytical standard, for drug analysis
Sigma-Aldrich
Acetaminophen, BioXtra, ≥99.0%
Sigma-Aldrich
Aspirin, meets USP testing specifications
Sigma-Aldrich
Hydrochlorothiazide, meets USP testing specifications
Sigma-Aldrich
Digitoxin, ≥92% (HPLC), powder
Sigma-Aldrich
5,5-Diphenylhydantoin, ≥98%
Sigma-Aldrich
6-Propyl-2-thiouracil, enzyme inhibitor
Sigma-Aldrich
Gabapentin, solid
Supelco
Busulfan, analytical standard, for drug analysis
Sigma-Aldrich
Caffeine, BioXtra
Sigma-Aldrich
Hydrochlorothiazide, crystalline
Sigma-Aldrich
Mycophenolic acid, ≥98%
Sigma-Aldrich
Caffeine, powder, ReagentPlus®
Sigma-Aldrich
Caffeine, Sigma Reference Standard, vial of 250 mg
Supelco
Testosterone solution, 1.0 mg/mL in 1,2-dimethoxyethane, drug standard
Sigma-Aldrich
Mycophenolic acid, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Caffeine, meets USP testing specifications, anhydrous
Sigma-Aldrich
Glyburide, meets USP testing specifications
Sigma-Aldrich
Piroxicam, meets USP testing specifications